Impact of SARS-CoV-2 infection on patients with hematological malignancies: a retrospective study

Figures & data

Table 1. Clinical characteristic and outcome of the patients with hematologic malignancies and SARS-Cov2 infection (n  =  74).

Items	Mild/moderate	Severe/critical	P-value	Survivor	Non-survivor	P-value
Gender, n (%)
Male	39 (86.7)	6 (13.3)	P = 0.899	41 (91.1)	4 (8.9)	P = 0.780
Female	24 (82.8)	5 (17.2)		25 (86.2)	4 (13.8)
Age range, n (%)
<60 y	48 (85.7)	8 (14.3)	P = 1.000	51 (91.1)	5 (8.9)	P = 0.629
≥60 y	15 (83.3)	3 (16.7)		15 (83.3)	3 (16.7)
Diagnosis, n (%)
AML	17 (70.8)	7 (29.2)	P = 0.063^△	18 (75.0)	6 (25.0)	P = 0.140^△
ALL	8 (72.7)	3 (27.3)		10 (90.9)	1 (9.1)
MM	8 (100)	0		8 (100.0)	0
Lymphoma	19 (100)	0		19 (100.0)	0
MDS	3 (100)	0		3 (100.0)	0
CML	2 (100)	0		2 (100.0)	0
CLL	2 (66.7)	1 (33.3)		2 (66.7)	1 (33.3)
Others	4 (100)	0		4 (100.0)	0
AML diagnosis, n (%)
Yes	17 (70.8)	7 (29.2)	P = 0.041	18 (75.0)	6 (25.0)	P = 0.020
No	46 (92.0)	4 (8.0)		48 (96.0)	2 (4.0)
Ethnicity, n (%)
Han	38 (86.4)	6 (13.6)	P = 0.579^△	40 (90.9)	4 (9.1)	P = 0.467^△
Zhuang minority	23 (85.2)	4 (14.8)		24 (88.9)	3 (11.1)
Others	2 (66.7)	1 (33.3)		2 (66.7)	1 (33.3)
Comorbidity, n (%)
No	39 (86.7)	6 (13.3)	P = 0.488^△	40 (88.9)	5 (11.1)	P = 0.344^△
Hypertension	7 (87.5)	1 (12.5)		8 (100.0)	0
Diabetes	1 (50.0)	1 (50.0)		1 (50.0)	1 (50.0)
Others	16 (84.2)	3 (15.8)		17 (89.5)	2 (10.5)
SARS-CoV-2 infection occurred during chemotherapy period, n (%)
Yes	13 (81.3)	3 (18.8)	P = 0.923	15 (93.8)	1 (6.3)	P = 0.835
No	51 (86.2)	8 (13.8)		51 (87.9)	7 (12.1)
SARS-CoV-2 infection occurred during neutropenic phase, n (%)
Yes	12 (100)	0	P = 0.255	12 (100)	0	P = 0.418
No	51 (82.3)	11 (17.7)		54 (87.1)	8 (12.9)
Primary disease states, n (%)
Active state	22 (71.0)	9 (29.0)	P = 0.010	25 (80.6)	6 (19.4)	P = 0.103
Stable state	41 (95.3)	2 (4.7)		41 (95.3)	2 (4.7)
Nirmatrelvir/ritonavir administration, n (%)
Yes	28 (77.8)	8 (22.2)	P = 0.083	31 (86.1)	5 (13.9)	P = 0.649
No	35 (92.1)	3 (7.9)		35 (92.1)	3 (7.9)
Hospitalization days, median (IQR)	11 (5–21)	23 (14–31)	P = 0.019^#	12 (5–23.5)	24 (11–44.5)	P = 0.080^#
Body-Mass Index (MBI), Mean ±SD	21.83 ± 3.37	22.04 ± 2.04	P = 0.776	21.80 ± 3.31	22.33 ± 2.23	P = 0.663
Lowest ORF1ab RNA cycle threshold values, Mean ±SD	30.47 ± 4.33	28.19 ± 3.93	P = 0.108	30.38 ± 4.27	28.03 ± 4.49	P = 0.147
Lowest N RNA cycle threshold values, Mean ±SD	30.87 ± 4.42	28.64 ± 4.14	P = 0.124	30.76 ± 4.38	28.67 ± 4.67	P = 0.208
Chemotherapy after negative SARS-CoV-2 infection (n = 23), n (%)
Waiting <14 days	15 (93.8)	1 (6.3)	P = 0.526^△	15 (93.8)	1 (6.3)	P = 1.000^△
Waiting ≥14 days	6 (85.7)	1 (14.3)		7 (100.0)	0

Notes: AML, Acute Myeloid Leukemia, ALL, Acute Lymphatic Leukemia, MM, Multiple Myeloma, CML, Chronic Myeloid Leukemia, CLL, Chronic Lymphocytic Leukemia, MDS, Myelodysplastic Syndrome. IQR, Interquartile range, SD, Standard deviation. ^△Fisher’s exact tests, ^#Mann–Whitney U-tests.